Materialise(MTLS)2025-02-20 13:09Revenue Performance - Total revenue for Q4 2024 increased by 0.6% to €65,680 k from €65,295 k in Q4 2023, driven by a 14.3% growth in the Materialise Medical segment[5] - For the full year 2024, total revenues increased by 4.2% to €266,765 k from €256,127 k in 2023, with a gross profit margin of 56.5%[9] - Revenue for the three months ended December 31, 2024, was 65,680,000 in the same period of 2023[30] - Total revenues for the three months ended December 31, 2024, reached €65,680,000, a slight increase from €65,295,000 in the same period of 2023[40] - The total revenues for the twelve months ended December 31, 2024, were €266,765,000, an increase from €256,127,000 in 2023, representing a growth of 4.1%[40] Segment Performance - Materialise Medical segment revenue grew by 14.3% to €31,837 k in Q4 2024, with an Adjusted EBITDA margin of 30.0%, down from 33.6% in the prior year[6] - Materialise Software segment revenue decreased by 1.1% to €11,124 k in Q4 2024, with an Adjusted EBITDA margin of 10.1%, down from 11.2% in the previous year[7] - Materialise Manufacturing segment revenue fell by 13.3% to €22,719 k in Q4 2024, resulting in an Adjusted EBITDA margin of (13.2)%, compared to 2.1% in Q4 2023[8] - Segment adjusted EBITDA for the Medical segment for the twelve months ended December 31, 2024, was €35,562,000, representing an increase from €26,544,000 in 2023, a growth of 34%[40] - The Software segment's adjusted EBITDA margin for the three months ended December 31, 2024, was 10.1%, down from 11.2% in the same period of 2023[40] Profitability - Adjusted EBITDA for Q4 2024 decreased to €4,306 k from €8,474 k in the same period last year, while Adjusted EBIT amounted to (€1,195) k compared to €3,154 k in Q4 2023[5] - Net profit for 2024 was €13,406 k, or €0.23 per diluted share, compared to €6,695 k, or €0.11 per diluted share in 2023[19] - Net profit for the twelve months ended December 31, 2024, was 6,695,000 in 2023, representing a 100.5% increase[34] - Adjusted EBIT for the twelve months ended December 31, 2024, was €9,741,000, compared to €9,886,000 for the same period in 2023, indicating a decrease of 1.5%[38] - Total comprehensive income for the twelve months ended December 31, 2024, was 7,619,000 in 2023, reflecting a growth of 52.3%[31] Cash Flow and Capital Expenditures - Cash flow from operating activities for 2024 was €31,456 k, up from €20,157 k in 2023, with total capital expenditures of €26,377 k[21] - The company reported a net cash flow from operating activities of 20,157,000 in 2023, an increase of 56.0%[34] - Total cash reserves at the end of 2024 amounted to €102,304 k, down from €127,573 k at the end of 2023[20] - Cash and cash equivalents decreased to 127,573,000 in 2023, a decline of 19.8%[34] Expenses - Research and development expenses increased to 38,098,000 in 2023, reflecting a growth of 16.5%[30] - Corporate research and development expenses for the twelve months ended December 31, 2024, totaled €3,681,000, up from €2,785,000 in 2023[41] - Financial expenses for the twelve months ended December 31, 2024, were €4,516,000, compared to €3,865,000 in 2023, reflecting an increase of 16.8%[38] - The company incurred acquisition-related expenses of €24,000 in connection with the acquisition of Feops during the twelve months ended December 31, 2024[42] Assets and Equity - Total assets as of December 31, 2024, were 396,630,000 in 2023[32] - The company’s total equity attributable to the owners of the parent increased to 236,646,000 in 2023, a rise of 5.0%[33]